The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer.

The study examined genetic alterations in more than 3,200 patients with lung cancer, focusing on key genes linked to non-small cell lung ... while squamous cell carcinoma made up the remaining ...

IMA-203 is a gene-modified cell therapy commercialized by Immatics, with a leading Phase II program in Ovarian Cancer;Endometrial Cancer.

Bizengri (zenocutuzumab) targets the NRG1 gene and has been cleared by the FDA to treat advanced pancreatic adenocarcinoma ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming ...

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...